STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 97 filers reported holding STOKE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $334,900 | -62.9% | 85,000 | 0.0% | 0.28% | -57.9% |
| Q2 2023 | $903,550 | +722740.0% | 85,000 | +466.7% | 0.68% | +590.8% |
| Q1 2023 | $125 | -9.4% | 15,000 | 0.0% | 0.10% | +1.0% |
| Q4 2022 | $138 | -99.9% | 15,000 | 0.0% | 0.10% | -28.7% |
| Q3 2022 | $193,000 | -2.5% | 15,000 | 0.0% | 0.14% | -5.6% |
| Q2 2022 | $198,000 | -37.3% | 15,000 | 0.0% | 0.14% | -36.6% |
| Q1 2022 | $316,000 | -12.2% | 15,000 | 0.0% | 0.23% | -2.2% |
| Q4 2021 | $360,000 | -5.8% | 15,000 | 0.0% | 0.23% | -10.8% |
| Q3 2021 | $382,000 | -24.4% | 15,000 | 0.0% | 0.26% | -13.9% |
| Q2 2021 | $505,000 | -13.4% | 15,000 | 0.0% | 0.30% | -12.7% |
| Q1 2021 | $583,000 | -52.9% | 15,000 | -25.0% | 0.35% | -51.5% |
| Q4 2020 | $1,239,000 | -7.5% | 20,000 | -50.0% | 0.71% | +59.4% |
| Q3 2020 | $1,340,000 | +180.9% | 40,000 | +100.0% | 0.45% | +55.6% |
| Q2 2020 | $477,000 | +4.1% | 20,000 | 0.0% | 0.29% | -29.1% |
| Q1 2020 | $458,000 | – | 20,000 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
| RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
| Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
| Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
| Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
| HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
| Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
| Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |